Patient-derived tumor organoids are emerging as high-fidelity preclinical models for precision oncology, offering a way to test cancer treatments on three-dimensional cell clusters that mirror a patient’s specific disease. Recent research led by investigators at Weill Cornell Medicine demonstrates that these “avatars” can reliably predict treatment sensitivity, potentially expanding the pool of patients eligible for targeted therapies like PARP inhibitors.
Building a Library of Patient-Derived Avatars
Researchers at the Englander Institute for Precision Medicine at Weill Cornell Medicine have successfully developed a library of 220 tumor organoids derived from 190 patients. According to a study published June 26 in Science Advances, these models span 15 distinct cancer types. The team found that the organoids maintained key characteristics of the original tumors, including driver DNA mutations and specific gene expression patterns, over extended periods of growth.
The practical application of this library was tested using PARP inhibitors, a class of drugs often restricted to patients with specific genetic markers. When researchers tested the drug talazoparib on organoids from patients previously deemed ineligible for the treatment, they discovered that 58% of the models showed substantial sensitivity. This finding suggests that current clinical criteria may be excluding patients who could otherwise benefit from these therapies, according to Dr. Andrea Sboner, co-senior author of the study and director of informatics and computational biology at the Englander Institute.
Pro Tip: Unlike traditional two-dimensional cell cultures, organoids preserve the three-dimensional architecture of the parent tumor, which is critical for observing how drugs penetrate and interact with cancer cells in a more natural environment.
Recapitulating the Immune Microenvironment
A significant hurdle in cancer research has been replicating the tumor immune microenvironment, where T cells and other immune components dictate how a tumor responds to therapy. In a study published May 13 in Cell Reports Methods, Weill Cornell investigators developed methods to create lung tumor organoids that incorporate these essential immune elements.
Dr. M. Laura Martin, senior author of both studies and director of the tumor organoid platform at the Englander Institute at the time the research was performed, noted that these “immunocompetent” organoids are designed for high-throughput testing. By allowing researchers to observe T cell activity under various treatment regimens—including checkpoint inhibitors—these models provide a clearer picture of how a patient’s immune system might react to experimental drugs.
The Future of Precision Oncology
The long-term vision for this technology involves moving from general preclinical research to personalized patient care. Researchers are exploring the use of these organoids as “avatars” to guide treatment selection. By growing a sample of a patient’s tumor and testing it against multiple drug regimens, clinicians may eventually be able to identify the most effective course of action before administering treatment.
“It sounds like sci-fi but it’s not far away,” said Dr. Juan Miguel Mosquera, a co-senior author on the first study and director of research pathology at the Englander Institute. This approach could allow for early identification of potential side effects and treatment efficacy, fundamentally shifting how oncologists approach complex or resistant cases.
Did you know? Tumor organoids can be used to identify synergistic drug combinations, where two drugs working together prove more effective than either one used alone, according to findings from the Englander Institute team.
Frequently Asked Questions
What are tumor organoids?
They are three-dimensional clusters of cells grown from patient tumor samples that replicate the structural and functional features of the original cancer, serving as a model for testing treatments.
How do organoids help in clinical trials?
They act as “avatars,” allowing researchers to simulate how a patient’s tumor might respond to experimental therapies, which can provide early insights into treatment efficacy and potential side effects.
Can organoids include immune cells?
Yes. Recent methods developed at Weill Cornell Medicine allow for the creation of lung tumor organoids that include T cells and other immune components, enabling the study of immune-based cancer therapies.
Are you interested in the future of precision medicine? Subscribe to our newsletter for the latest updates on cancer research, or browse our archive of articles on emerging biomedical technologies.
Related reading